Related references
Note: Only part of the references are listed.Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats
Toru Miyoshi et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants
Shiying Wu et al.
CARDIOVASCULAR THERAPEUTICS (2014)
Antiatherothrombotic Effects of Dipeptidyl Peptidase Inhibitors
Alison Cameron-Vendrig et al.
CURRENT ATHEROSCLEROSIS REPORTS (2014)
Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
Keizo Kanasaki et al.
DIABETES (2014)
The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus
P. C. M. van Poppel et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition
Jessica K. Devin et al.
HYPERTENSION (2014)
Vascular Origin of Vildagliptin-induced Skin Effects in Cynomolgus Monkeys: Pathomechanistic Role of Peripheral Sympathetic System and Neuropeptide Y
Peter Hoffmann et al.
TOXICOLOGIC PATHOLOGY (2014)
Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs
Fiona M. Keane et al.
FEBS OPEN BIO (2014)
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
Eun Yeong Choe et al.
DIABETES & METABOLISM JOURNAL (2014)
Evaluating Second-Line Treatment Options for Type 2 Diabetes: Focus on Secondary Effects of GLP-1 Agonists and DPP-4 Inhibitors
Cassie L. Boland et al.
ANNALS OF PHARMACOTHERAPY (2013)
An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: Potential implications in cardiovascular disease
Jixin Zhong et al.
ATHEROSCLEROSIS (2013)
Dipeptidyl peptidases in atherosclerosis: expression and role in macrophage differentiation, activation and apoptosis
Veerle Matheeussen et al.
BASIC RESEARCH IN CARDIOLOGY (2013)
Glypican-3-mediated inhibition of CD26 by TFPI: a novel mechanism in hematopoietic stem cell homing and maintenance
Satish Khurana et al.
BLOOD (2013)
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor
Yuji Ishibashi et al.
CARDIOVASCULAR DIABETOLOGY (2013)
Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes
Stephane Dalle et al.
CELLULAR SIGNALLING (2013)
The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain A Comparison With Glimepiride
Vladimer Darsalia et al.
DIABETES (2013)
Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials
M. Monami et al.
DIABETES OBESITY & METABOLISM (2013)
Anagliptin, a DPP-4 Inhibitor, Suppresses Proliferation of Vascular Smooth Muscles and Monocyte Inflammatory Reaction and Attenuates Atherosclerosis in Male apo E-Deficient Mice
Nasib Ervinna et al.
ENDOCRINOLOGY (2013)
Protective effects of sitagliptin on myocardial injury and cardiac function in an ischemia/reperfusion rat model
Guanglei Chang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
CD26/DPP4 Levels in Peripheral Blood and T Cells in Patients With Type 2 Diabetes Mellitus
Sang Ah Lee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension
Lyubov Chaykovska et al.
JOURNAL OF HYPERTENSION (2013)
Advances in Understanding the Expression and Function of Dipeptidyl Peptidase 8 and 9
Hui Zhang et al.
MOLECULAR CANCER RESEARCH (2013)
A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients
Noriko Satoh-Asahara et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Lower dipeptidyl peptidase-4 following exercise training plus weight loss is related to increased insulin sensitivity in adults with metabolic syndrome
Steven K. Malin et al.
PEPTIDES (2013)
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction
Sheldon Russell
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2013)
DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
Matteo Monami et al.
ADVANCES IN THERAPY (2012)
Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients
Paul A. J. Krijnen et al.
BASIC RESEARCH IN CARDIOLOGY (2012)
Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells
Chun-Yao Huang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice
F. Briand et al.
DIABETES OBESITY & METABOLISM (2012)
Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe -/- mice
F. Vittone et al.
DIABETOLOGIA (2012)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
Dipeptidyl Peptidase IV Regulates Proliferation of Preglomerular Vascular Smooth Muscle and Mesangial Cells
Edwin K. Jackson et al.
HYPERTENSION (2012)
Augmentation of Kv4.2-encoded Currents by Accessory Dipeptidyl Peptidase 6 and 10 Subunits Reflects Selective Cell Surface Kv4.2 Protein Stabilization
Nicholas C. Foeger et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Enhanced Nitric Oxide Release and Reduced Blood Pressure and sICAM-1 Levels in Hypertensive Rats
R. Preston Mason et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2012)
Sitagliptin Exerts an Antinflammatory Action
Antoine Makdissi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy
Markus L. Alter et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis
Hal E. Broxmeyer et al.
NATURE MEDICINE (2012)
Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers
Ashish Kumar Gupta et al.
PLATELETS (2012)
Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
Matthias Kern et al.
PLOS ONE (2012)
Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats
Soo Lim et al.
PLOS ONE (2012)
Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice
Timo Rieg et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2012)
Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
Zubair Shah et al.
CIRCULATION (2011)
Dipeptidyl Peptidase 4 Is a Novel Adipokine Potentially Linking Obesity to the Metabolic Syndrome
Daniela Lamers et al.
DIABETES (2011)
Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
Pleun C. M. van Poppel et al.
DIABETES CARE (2011)
DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E-Deficient Mice
Nga N. Ta et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
Lyubov Chaykovska et al.
PLOS ONE (2011)
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis
Takanori Matsui et al.
PHARMACOLOGICAL RESEARCH (2011)
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Gian Paolo Fadini et al.
VASCULAR PHARMACOLOGY (2011)
Understanding the Cardiovascular Effects of Incretin
Ji Sung Yoon et al.
DIABETES & METABOLISM JOURNAL (2011)
DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes
Nga N. Ta et al.
ATHEROSCLEROSIS (2010)
Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition
Mark Kirby et al.
CLINICAL SCIENCE (2010)
The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes Possible role of stromal-derived factor-1α
Gian Paolo Fadini et al.
DIABETES CARE (2010)
The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice
J. Hsieh et al.
DIABETOLOGIA (2010)
Neuropeptide Y is a mediator of chronic vascular and metabolic maladaptations to stress and hypernutrition
Ken Abe et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2010)
Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
Annis Marney et al.
HYPERTENSION (2010)
Inhibition of CD26/DPP IV attenuates ischemia/reperfusion injury in orthotopic mouse lung transplants: The pivotal role of vasoactive intestinal peptide
Wolfgang Jungraithmayr et al.
PEPTIDES (2010)
On the origin of serum CD26 and its altered concentration in cancer patients
Oscar J. Cordero et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
Michael Boschmann et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
Duyen T. Dang et al.
CANCER RESEARCH (2008)
GLUCOSE REGULATION OF DIPEPTIDYL PEPTIDASE IV GENE EXPRESSION IS MEDIATED BY HEPATOCYTE NUCLEAR FACTOR-1α IN EPITHELIAL INTESTINAL CELLS
Ning Gu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2008)
Role of CD26/dipeptidyl peptidase IV in human T cell activation and function
Kei Ohnuma et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes
Peter R. Flatt et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
The role of CD26/dipeptidyl peptidase IV in cancer
Pamela A. Havre et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension
Edwin K. Jackson et al.
HYPERTENSION (2008)
Dipeptidyl peptidase IV inhibition downregulates Na+-H+ exchanger NHE3 in rat renal proximal tubule
Adriana Castello Costa Girardi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice
Grace Flock et al.
DIABETES (2007)
Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome
Lydia E. Kuo et al.
NATURE MEDICINE (2007)
The Simpson-Golabi-Behmel syndrome causative Glypican-3, binds to and inhibits the dipeptidyl peptidase activity of CD26
Jamshid Davoodi et al.
PROTEOMICS (2007)
Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1
Kei Ohnuma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
Jakob Ryskjaer et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
GR Lankas et al.
DIABETES (2005)
Circulating CD26 is negatively associated with inflammation in human and experimental arthritis
N Busso et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and function in the central nervous system
C Hawkes et al.
BRAIN RESEARCH REVIEWS (2004)
Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer
P Busek et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2004)
Modulation of hematopoietic stem cell homing and engraftment by CD26
KW Christopherson et al.
SCIENCE (2004)
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments
JM Lenhard et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen
SL Yan et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
The multifunctional or moonlighting protein CD26/DPPIV
E Boonacker et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2003)
Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex
G Ghersi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO
T Ishii et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease
M Hildebrandt et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2001)
CD26: A multifunctional integral membrane and secreted protein of activated lymphocytes
MD Gorrell et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2001)
Vesicular localization and characterization of a novel post-proline-cleaving aminodipeptidase, quiescent cell proline dipeptidase
M Chiravuri et al.
JOURNAL OF IMMUNOLOGY (2000)
Good or evil: CD26 and HIV infection
T Ohtsuki et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2000)
Regulation of CD26/DPPIV gene expression by interferons and retinoic acid in tumor B cells
B Bauvois et al.
ONCOGENE (2000)
Share Paper
